Seven Fleet Capital Management LP Cuts Stake in Eupraxia Pharmaceuticals Inc. $EPRX

Seven Fleet Capital Management LP cut its position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) by 13.9% in the second quarter, HoldingsChannel.com reports. The firm owned 610,785 shares of the company’s stock after selling 98,730 shares during the period. Seven Fleet Capital Management LP’s holdings in Eupraxia Pharmaceuticals were worth $4,037,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Redmile Group LLC purchased a new stake in Eupraxia Pharmaceuticals in the first quarter valued at about $5,068,000. Rubric Capital Management LP purchased a new position in shares of Eupraxia Pharmaceuticals in the first quarter worth about $5,004,000. DV Trading LLC purchased a new position in Eupraxia Pharmaceuticals during the 1st quarter worth approximately $1,998,000. Cibc World Market Inc. acquired a new position in Eupraxia Pharmaceuticals during the second quarter valued at $1,539,000. Finally, Jupiter Topco LLC acquired a new position in shares of Eupraxia Pharmaceuticals in the 2nd quarter valued at about $6,851,000.

Analysts Set New Price Targets

EPRX has been the subject of several recent analyst reports. Oppenheimer began coverage on Eupraxia Pharmaceuticals in a research note on Thursday, June 25th. They issued an “outperform” rating and a $17.00 price target for the company. Stifel Nicolaus began coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, May 21st. They issued a “buy” rating and a $25.00 price target for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen downgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a research report on Wednesday, July 15th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Eupraxia Pharmaceuticals Stock Performance

Shares of Eupraxia Pharmaceuticals stock opened at $8.40 on Friday. Eupraxia Pharmaceuticals Inc. has a one year low of $5.15 and a one year high of $9.32. The company has a market cap of $546.17 million, a price-to-earnings ratio of -8.24 and a beta of 1.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 16.00 and a current ratio of 16.00. The business’s 50 day moving average price is $6.68 and its 200 day moving average price is $7.00.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last issued its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.02. On average, research analysts predict that Eupraxia Pharmaceuticals Inc. will post -0.87 EPS for the current year.

Eupraxia Pharmaceuticals Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.